Product Description
Mopac Biologics is developing best-in-class oral and topical biologic therapies for autoinflammatory diseases. Mopac uses computational protein design technology originating at the University of Washington that uniquely enables discovery of therapeutics with desirable properties, including extremely high potency and resistance to gastrointestinal conditions. With their drug discovery capabilities and world-class development team, Mopac aims to bring safe, effective, and convenient therapies to the clinic. Their lead molecule, MB1, is an oral protein inhibitor of IL-23R in preclinical development for treatment of Inflammatory Bowel Disease. (Sourced from: https://www.bionebraska.org/welcome-mopac-biologics/)
Mechanisms of Action: IL23 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mopac Biologics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Inflammatory Bowel Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|